Adcetris is definitely more active in HL, but it does seem to have activity in CD30+ NHL as well. I'm curious to see the combo data w opdivo in NHL. Adcetris + opdivo in HL was just presented and showed a near doubling of the CR rate vs adcetris monotherapy in post transplant relapsers from 34% to 62%
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.